
Keywords: Tyrosine kinase inhibitors; Drug transporter; Drug interaction; Therapeutic drug monitoring; Skin disorders; ADR; Adverse drug reaction; AUC; Area under the curve; BBB; Blood-brain barrier; BCRP/ABCG2; Breast cancer resistance protein; CNS; Central nerv